ABT ▲ +0.0% - Abbott Laboratories
$ABT - Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
26-OCT-2026 09:01 AM ET
Share this post
More filings for $ABT
ABT ▲ +0.1% - Abbott LaboratoriesNov 2, 2026ABT ▲ +1.6% - Abbott LaboratoriesNov 1, 2026ABT ▲ +1.5% - Abbott LaboratoriesOct 29, 2026ABT ▼ -0.4% - Abbott LaboratoriesOct 23, 2026ABT ▼ -3.4% - Abbott LaboratoriesOct 21, 2026ABT ▼ -1.6% - Abbott LaboratoriesOct 21, 2026
View full $ABT filing history →💬 Comments
Loading comments…
Leave a comment